HQY vs VRTX
HealthEquity vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
VS
VRTX
Vertex Pharmaceuticals
66
Buy
| Metric | HQY | VRTX |
|---|
| AI Score |
64
|
66
|
| Price |
$106.83
|
$523.89
|
| P/E Ratio |
38.75×
|
28.64×
|
| ROE |
10.2%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.7%
|
86.0%
|
| Debt / Equity |
0.48×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.8
|
66.6
|
| Beta |
0.21
|
0.305
|
| Expected Upside |
+1.0%
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for HQY versus VRTX.
VRTX leads by 2 points.
VRTX scores 66/100 (Buy) versus HQY at 64/100 (Buy).
HQY Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 4 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 15.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly RSI at 76 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 15.3% signals elevated volatility — Risk
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical